Immunotherapy combo shows promise in shrinking oral tumors before surgery
NCT ID NCT02919683
First seen Feb 01, 2026 · Last updated May 11, 2026 · Updated 11 times
Summary
This study tested two immunotherapy drugs, nivolumab and ipilimumab, given before surgery to people with oral cavity squamous cell carcinoma. The goal was to see if the drugs could shrink tumors and be safe. 30 adults with stage T2 or higher tumors took part. The approach aims to improve outcomes by using the body's immune system to fight cancer before surgical removal.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.